--- title: "Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated…" description: "Omega-3 fatty acid supplementation can reduce the risk of certain cardiovascular events, with greater benefits potentially seen at higher doses." url: "https://magellanlongevity.com/study/d32951855.md" canonical: "https://magellanlongevity.com/study/d32951855.html" html: "https://magellanlongevity.com/study/d32951855.html" type: "study" study_key: "d32951855" journal: "Mayo Clin Proc" year: 2020 pmid: "32951855" doi: "10.1016/j.mayocp.2020.08.034" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis of Interventional Trials [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Effect of Omega-3 Dosage on Cardiovascular Outcomes: An… **HTML version:** https://magellanlongevity.com/study/d32951855.html · **In the Magellan app:** https://magellanlongevity.com/#/study/d32951855 ## Citation | Field | Value | | --- | --- | | Journal | Mayo Clin Proc | | Year | 2020 | | PMID | [32951855](https://pubmed.ncbi.nlm.nih.gov/32951855/) | | DOI | [10.1016/j.mayocp.2020.08.034](https://doi.org/10.1016/j.mayocp.2020.08.034) | | Study key | d32951855 | ## Takeaway Omega-3 fatty acid supplementation can reduce the risk of certain cardiovascular events, with greater benefits potentially seen at higher doses. ## The question What is the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention, and how does dosage influence this effect? ## Hypothesis The study implicitly hypothesizes that EPA/DHA supplementation will reduce the risk of cardiovascular events and that this effect may be dose-dependent. ## Methods This study is a random effects meta-analysis and meta-regression of randomized controlled trials (RCTs) involving EPA/DHA supplementation and cardiovascular outcomes. It included RCTs published before August 2019, covering outcomes such as myocardial infarction (MI), coronary heart disease (CHD) events, CVD events, CHD mortality, and fatal MI. The Grading of Recommendations Assessment, Development, and Evaluation framework was used to assess the strength of evidence. ## Results Forty studies with 135,267 participants were included. Supplementation was associated with a reduced risk of MI (RR, 0.87), CHD events (RR, 0.90), fatal MI (RR, 0.65), and CHD mortality (RR, 0.91). No significant reduction was observed for overall CVD events (RR, 0.95). The protective effect was found to be dose-dependent for CVD events and MI. ## Conclusion Supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect likely increases with dosage. ## Limitations The abstract does not explicitly state limitations of the study, but as a meta-analysis, it is dependent on the quality and reporting of the included individual studies. ## Verbatim from the abstract > Supplementation with EPA and DHA is an effective lifestyle strategy for cardiovascular disease prevention ## Relative Risk Reduction with Omega-3 Supplementation | Measure | Relative Risk (RR) | | --- | --- | | Myocardial Infarction (MI) | 0.87 | | Coronary Heart Disease (CHD) Events | 0.9 | | Fatal MI | 0.65 | | CHD Mortality | 0.91 | | CVD Events (composite) | 0.95 | *Relative risk (RR) for various cardiovascular outcomes with EPA/DHA supplementation. An RR less than 1 indicates a reduced risk.* ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Omega-3 EPA/DHA Fish Oil | Moderate evidence | [Omega-3 EPA/DHA Fish Oil](https://magellanlongevity.com/p/128.md) | ## Reference 1. **Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis of Interventional Trials** Mayo Clin Proc 2020 · [PMID 32951855](https://pubmed.ncbi.nlm.nih.gov/32951855/) · [DOI 10.1016/j.mayocp.2020.08.034](https://doi.org/10.1016/j.mayocp.2020.08.034) > Supplementation with EPA and DHA is an effective lifestyle strategy for cardiovascular disease prevention ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/d32951855.html#page","url":"https://magellanlongevity.com/study/d32951855.html","name":"Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis of Interventional Trials","description":"Omega-3 fatty acid supplementation can reduce the risk of certain cardiovascular events, with greater benefits potentially seen at higher doses.","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/d32951855.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Effect of Omega-3 Dosage on Cardiovascular Outcomes: An…","item":"https://magellanlongevity.com/study/d32951855.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/d32951855.html#study","name":"Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis of Interventional Trials","headline":"Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis of Interventional Trials","datePublished":"2020","isPartOf":{"@type":"Periodical","name":"Mayo Clin Proc"},"identifier":"PMID:32951855","url":"https://pubmed.ncbi.nlm.nih.gov/32951855/","sameAs":"https://doi.org/10.1016/j.mayocp.2020.08.034","abstract":"Omega-3 fatty acid supplementation can reduce the risk of certain cardiovascular events, with greater benefits potentially seen at higher doses."}]} ``` ## Related on Magellan Longevity - [Omega-3 EPA/DHA Fish Oil](https://magellanlongevity.com/p/128.md) — product graded on this and related evidence - [Evidence: anti-inflammatory long-chain PUFAs](https://magellanlongevity.com/study/s128.md) - [Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and…](https://magellanlongevity.com/study/d34505026.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).